Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are increasingly recognised for their role in cardiovascular (CV) physiology. The GH-IGF-1 axis plays an essential role in the development ...of the CV system as well as in the complex molecular network that regulates cardiac and endothelial structure and function. A considerable correlation between GH levels and CV mortality exists even among individuals in the general population without a notable deviation in the GHIGF- 1 axis functioning. In addition, over the last decades, evidence has demonstrated that pathologic conditions involving the GH-IGF-1 axis, as seen in GH excess to GH deficiency, are associated with an increased risk for CV morbidity and mortality. A significant part of that risk can be attributed to several accompanying comorbidities. In both conditions, disease control is associated with a consistent improvement of CV risk factors, reduction of CV mortality, and achievement of standardised mortality ratio similar to that of the general population. Data on the prevalence of peripheral arterial disease in patients with acromegaly or growth hormone deficiency and the effects of GH and IGF-1 levels on the disease progression is limited. In this review, we will consider the pivotal role of the GH-IGF-1 axis on CV system function, as well as the far-reaching consequences that arise when disorders within this axis occur, particularly in relation to the atherosclerosis process.
Risk stratification in patients with unstable angina remains a challenging task. Troponins, electrocardiographic changes and clinical characteristics are the most widely employed parameters. Blood ...pressure and heart rate are proven predictors of short-term outcome; no study, however, has investigated the dynamics of these variables. We postulated that measurements of these parameters performed at the beginning of an ischemic episode would reflect the extent of coronary disease and would predict short-term outcome.
Analysis of variance and multivariate logistic regression were used to analyze the relationship of systolic blood pressure and heart rate during ischemic episodes with the occurrence of adverse ischemic events (death, infarction, need for revascularization) prior to hospital discharge.
In a group of 193 patients mortality rate was 4.2%, infarction rate 8.4% and revascularization rate 42.4%. Systolic blood pressure increased during ischemic episodes compared to baseline values in the group of survivors (p < 0.0001), while there were no significant changes in the group of non-survivors. The rise in heart rate during ischemic episodes was greater in non-survivors, even though significant changes were observed in both groups. Systolic pressure and heart rate were independent predictors of mortality (p = 0.01 and p = 0.003, respectively), but were not predictive of infarction or revascularization.
Low systolic blood pressure and high heart rate at the beginning of an ischemic episode predict higher in-hospital mortality in patients with unstable angina. Clinical presentation during the ischemic episode should be considered in risk stratification.
